GB
Gregory B. Brown
Chairman of the Board; Director and Chief Executive Officer of Memgen, LLC
Aquestive TherapeuticsTherapeutic Areas
Aquestive Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Anaphylm™ (AQST-109) | Severe allergic reactions, including anaphylaxis | Phase 3 |
| Libervant® (diazepam buccal film) | Seizure emergencies (e.g., acute repetitive seizures) | Approved |
| Epinephrine Prodrug Topical Gel | Possible various dermatology conditions | Pre-clinical |
| Licensed Commercial Products (Portfolio) | Various (CNS and others) | Commercial |
Leadership Team at Aquestive Therapeutics
DB
Daniel Barber
President, Chief Executive Officer, and Director
PB
Peter Boyd
Chief People Officer
LJ
Lori J. Braender
Chief Legal Officer, Chief Compliance Officer, and Secretary
MT
Melina T. Cioffi
Senior Vice President, Regulatory Affairs
MW
Matthew W. Davis
Chief Development Officer
MG
Matthew Greenhawt
Chief Medical Officer
CJ
Cassie Jung
Chief Operating Officer
SK
Sherry Korczynski
Chief Commercial Officer
ET
Ernie Toth
Chief Financial Officer
JC
John Cochran
Director; Partner at Bratton Capital Management L.P. / Partner & COO of Crestline Investors, Inc.